Route 92 Medical

Route 92 Medical is a privately held U.S. medical device company focused on neurovascular intervention. The company describes its mission as improving outcomes for patients undergoing neurovascular intervention through a reconsidered procedural approach, cutting-edge engineering, and innovative product design. Its portfolio targets unmet needs in neurointervention, particularly the challenges of navigating large-bore and super-bore catheters through tortuous anatomy and reaching target locations quickly and reliably during stroke treatment. The company was founded by physicians working with leading clinicians to develop product solutions aimed at improving procedural and patient outcomes. Its founder and Chief Executive Officer is Dr. Tony Chou, an academic interventional cardiologist and medical device industry executive with over 30 years of healthcare experience. Dr. Chou trained in cardiology and interventional cardiology at UCSF and previously served as Director of the Adult Cardiac Catheterization Laboratories at UCSF Moffitt-Long Hospitals. He later held roles at Abbott Laboratories and Abbott Vascular, including Division Vice President and General Manager of Vascular Closure, and became a General Partner of the healthcare-focused venture capital firm The Vertical Group in 2006. Route 92 Medical's flagship commercial platform is the FreeClimb Catheter System, powered by Tenzing. The FreeClimb 54, FreeClimb 70, and FreeClimb 88 catheter systems are advanced neurointervention systems designed to provide superior performance even in the most tortuous anatomy. The system combines the FreeClimb catheter with the Tenzing delivery catheter and the Base Camp sheath to provide a refined bi-axial setup intended to increase efficiency. According to company materials, this setup helps clinicians reach the target site without a guidewire in 71% of cases and streamlines delivery with large-bore (070) and super-bore (088) catheters. The company is also developing the HiPoint Reperfusion System, which features the Monopoint Approach. The SUMMIT MAX trial is underway to evaluate the safety and efficacy of the HiPoint Reperfusion System. The platform was designed to streamline delivery and enable super-bore aspiration at the most common stroke targets. The HiPoint Reperfusion System is currently an investigational device, limited by federal (or United States) law to investigational use. Route 92 Medical is backed by investors including Novo Holdings, InnovaHealth Partners, and Norwest Venture Partners. Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation and is a world-leading life sciences investor. InnovaHealth Partners is a New York-based private equity firm providing growth capital to the medical technology industry. Norwest Venture Partners is a venture and growth equity investment firm managing more than $12.5 billion in capital. The company is privately held and operates primarily in the United States.

Route 92 Medical was founded by physicians developing thoughtful product solutions in collaboration with the world's leading clinicians focused on improving procedural and patient outcomes. The company's founder and Chief Executive Officer is Dr. Tony Chou, who has over 30 years of healthcare experience as both an academic interventional cardiologist and medical device industry executive. Dr. Chou completed his cardiology and interventional cardiology training at UCSF and previously served as Director of the Adult Cardiac Catheterization Laboratories at UCSF Moffitt-Long Hospitals as a fulltime faculty member. His industry experience started as part of the corporate/business development team at Abbott Laboratories, and he transitioned to various positions in general management and business development in the business unit which became known as Abbott Vascular. As Division Vice President and General Manager of Vascular Closure, he oversaw the development, manufacturing, clinical trials, FDA PMAS/PMA, international regulatory registration and global launches of the femoral closure devices Perclose ProGlide and StarClose SE. Dr. Chou became a General Partner of the healthcare-focused venture capital firm The Vertical Group in 2006. The company is focused on neurovascular intervention, with a mission to improve outcomes for patients undergoing neurovascular intervention. Its approach centers on a reconsidered procedural approach, cutting-edge engineering, and innovative product design. The portfolio takes aim at the biggest challenges in neurointervention to deliver meaningful solutions. Route 92 Medical has developed the FreeClimb Catheter System, powered by Tenzing. The FreeClimb 54, FreeClimb 70, and FreeClimb 88 catheter systems are advanced neurointervention systems designed to provide superior performance even in the most tortuous anatomy. The system brings the FreeClimb catheter together with the Tenzing delivery catheter and the Base Camp sheath to provide a refined bi-axial setup for increased efficiency. According to company materials, this setup helps clinicians reach the target site without a guidewire in 71% of cases and streamlines delivery with large-bore (070) and super-bore (088) catheters. The company is also developing the HiPoint Reperfusion System, which features the Monopoint Approach. The SUMMIT MAX trial is currently underway to evaluate the safety and efficacy of the HiPoint Reperfusion System. The platform was designed to streamline delivery and enable super-bore aspiration at the most common stroke targets. The HiPoint Reperfusion System is an investigational device, limited by federal (or United States) law to investigational use. Route 92 Medical is backed by investors including Novo Holdings, InnovaHealth Partners, and Norwest Venture Partners. Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world's largest philanthropic enterprise foundations. InnovaHealth Partners is a New York-based private equity firm providing growth capital to the medical technology industry. Norwest Venture Partners is a venture and growth equity investment firm managing more than $12.5 billion in capital.

• 2006

  Tony Chou becomes a General Partner of The Vertical Group

• FreeClimb Catheter System powered by Tenzing is commercialized

• SUMMIT MAX trial underway to evaluate the HiPoint Reperfusion System

Advanced neurovascular intervention systems designed to overcome limitations of conventional devices in tortuous anatomy and streamline stroke intervention.

• FreeClimb 54 Catheter System

  Advanced neurointervention system designed for superior performance in tortuous anatomy.

• FreeClimb 70 Catheter System

  Large-bore (070) catheter system for streamlined delivery.

• FreeClimb 88 Catheter System

  Super-bore (088) catheter system for streamlined delivery.

• Tenzing Delivery Catheter

  Delivery catheter with a tapered, atraumatic tip designed to follow the natural flow of blood and seek the primary vessel.

• Base Camp Sheath

  Provides access and a stable base for delivering large-bore and super-bore catheters from a single rotating hemostatic valve (RHV).

• HiPoint Reperfusion System

  Investigational device featuring the Monopoint Approach, designed to streamline delivery and enable super-bore aspiration at the most common stroke targets.

1. 1Route 92 Medicalroute92medical.com
2. 2About Route 92 Medicalroute92medical.com
3. 3Refining Access - Route 92 Medicalroute92medical.com
4. 4Information for Investors - Route 92 Medicalroute92medical.com
5. 5Route 92 Medical, Inc.wikidata.org